<DOC>
	<DOCNO>NCT01817946</DOCNO>
	<brief_summary>Myotubular myopathy ( XLMTM ) X-linked disorder cause mutation myotubularin gene ( MTM1 ) . The clinical spectrum variable range individual require wheelchair full time breathe support able walk breathe . Symptoms myotubular myopathy include long face , facial weakness eye muscle weakness , breathe support muscle biopsy demonstrate central nucleated fiber . These symptom may cause mutation change MTM1 , BIN1 ( bridge integrator 1 ) , DNM2 ( dynamin 2 ) RYR1 ( ryanodine receptor 1 ) gene . However , majority cause mutation MTM1 gene . Some patient symptoms consistent myotubular myopathy initially negative test MTM1 gene later find unique type change MTM1 gene . This unique change , call deletion duplication , find different type genetic test call CGH ( comparative genomic hybridization ) array . Investigators know frequent deletion duplication patient X-linked myotubular myopathy . Recently , advance identify potential treatment XLMTM . The next step proceed clinical trial potential treatment . In order ready clinical trial , important investigator find specific genetic change cause XLMTM people diagnosis . This study attempt find change MTM1 gene individual clinical symptom consistent diagnosis XLMTM . Participants ask enroll CMDIR ( Congenital Muscle Disease International Registry ) , complete brief clinical survey , provide access medical record , provide saliva blood sample genetic testing . Results genetic testing communicate participant physician specify consent sign person . Study Hypothesis : Not individual clinical diagnosis XLMTM access genetic testing . Investigators know deletion duplication MTM1 gene cause XLMTM . Investigators find individual XLMTM perform genetic test MTM1 gene , include CGH array deletion duplication .</brief_summary>
	<brief_title>Myotubular Myopathy Genetic Testing Study</brief_title>
	<detailed_description>- Prospective participant complete registration CMDIR . - The CMDIR genetic curator review CMDIR data study eligibility . - If eligible , participant call consent participate study . - Sequencing do saliva sample . However , method detect mutation change MTM1 gene , test , call CGH Array , perform . For CGH Array test , saliva sample may deliver clear result term deletion/duplication mutation . In event , CGH Array saliva sample provide result , blood sample necessary repeat CGH Array . - The study participant receive kit instruction saliva specimen collection genetic test CMDIR mail . - If mutation change MTM1 gene could find genetic test CGH Array saliva sample , study participant receive second kit mail CMDIR instruction blood draw use CGH Array . - The family coordinate collection saliva specimen local blood draw , necessary , responsible mail specimen pre-paid parcel University Chicago . There $ 40 reimbursement cost blood draw . Mailing specimen test site cost participant . A two-week turn-around receipt kit send test laboratory request . - Genetic test start standard sequence MTM1 gene , isolate saliva specimen , follow CGH Array sequence MTM1 gene isolate saliva sample blood sample variant consistent symptom could detect use saliva sample . - Test result 1 ) report physician specify study participant 2 ) upload study participant 's profile CMDIR 3 ) concurrently enrol Beggs Laboratory IRB-approved clinical study , test result also make available study provide appropriate informed consent give .</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Myopathies , Structural , Congenital</mesh_term>
	<criteria>Patient eligibility determine CMDIR genetic curator use follow prioritization protocol . 1 . Males females US Canada know mutation MTM1 gene identify research lab never confirm clinical CLIA ( Clinical Laboratory Improvement Amendments ) certify laboratory . 2 . Male female patient US Canada meet 2 3 follow criterion : + clinical history , + family history , + centronucleation muscle biopsy ( sign nemaline rod core ) . Clinical history include : postnatal breathe support ( necessarily continue first month ) , length 90 % EGA ( estimate gestational age ) , facial characteristic ( narrow facies ) , facial weakness ( ophthalmoplegia , excessive saliva need suction ) . 3 . Males females US Canada present XLMTM symptom genetic mutation MTM1 gene find conventional sequencing , require CGH array deletion/duplication test . 4 . Age range : One month maximum age . 5 . Individual register CMDIR . 6 . Written study consent provide parent/caregiver ( affected individual 's age le 18 year individual great 18 year learn disability inability physically access consent ) affect individual ( age great 18 year ) 1 . Carrier test asymptomatic mother .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Congenital Myopathy</keyword>
	<keyword>Centronuclear Myopathy</keyword>
	<keyword>Myotubular Myopathy</keyword>
	<keyword>Myotubularin</keyword>
	<keyword>MTM1 Gene</keyword>
	<keyword>Genetic testing</keyword>
	<keyword>Sequencing</keyword>
	<keyword>Deletion/Duplication Mutation</keyword>
	<keyword>CGH array</keyword>
</DOC>